NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$121.07 -0.08 (-0.07 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$121.07
Today's Range$120.11 - $121.69
52-Week Range$96.18 - $149.34
Volume1.10 million shs
Average Volume2.23 million shs
Market Capitalization$26.94 billion
P/E Ratio23.46
Dividend YieldN/A
Beta1.11

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Debt-to-Equity Ratio0.33
Current Ratio3.35
Quick Ratio2.86

Price-To-Earnings

Trailing P/E Ratio23.46
Forward P/E Ratio19.28
P/E Growth1.09

Sales & Book Value

Annual Sales$3.55 billion
Price / Sales7.59
Cash Flow$8.0338 per share
Price / Cash15.07
Book Value$40.96 per share
Price / Book2.96

Profitability

EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins14.46%
Return on Equity13.70%
Return on Assets9.00%

Miscellaneous

Employees2,525
Outstanding Shares222,500,000

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals declared that its board has initiated a stock repurchase program on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company's leadership believes its stock is undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals (NASDAQ:ALXN) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.50 by $0.18. The biopharmaceutical company had revenue of $930.90 million for the quarter, compared to analysts' expectations of $920.50 million. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $1.38 EPS. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

What price target have analysts set for ALXN?

21 brokers have issued 12-month price objectives for Alexion Pharmaceuticals' shares. Their forecasts range from $120.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $156.8571 in the next twelve months. View Analyst Ratings for Alexion Pharmaceuticals.

What are Wall Street analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alexion beat on both earnings and sales in the first quarter of 2018 driven by strength of blockbuster drug Soliris which continues to perform well. The FDA approval for the generalized myasthenia gravis indication has boosted sales further. The prospects of ALXN1210 looks good too given the positive data from the switch study and in treatment-naïve patients. The increase in guidance was also encouraging. Meanwhile, Alexion is looking to diversify its portfolio and reduce its dependence on Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease. Shares of the company have performed better than the industry in the last six months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also imapct sales." (5/2/2018)
  • 2. JPMorgan Chase analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 55)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
  • Ms. Julie O'Neill MBA, Exec. VP of Global Operations (Age 62)
  • Mr. John B. Moriarty Jr., Former Exec. VP & Gen. Counsel (Age 50)
  • Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)

Has Alexion Pharmaceuticals been receiving favorable news coverage?

Press coverage about ALXN stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 50.21 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.03%), Northern Trust Corp (1.28%), Franklin Resources Inc. (1.00%), BB Biotech AG (0.63%), Wells Fargo & Company MN (0.59%) and Eaton Vance Management (0.52%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which institutional investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Amundi Pioneer Asset Management Inc., State of Tennessee Treasury Department, Franklin Resources Inc., American Century Companies Inc., Federated Investors Inc. PA, Prudential Financial Inc. and Nuveen Asset Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which institutional investors are buying Alexion Pharmaceuticals stock?

ALXN stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, PointState Capital LP, Redmile Group LLC, Westfield Capital Management Co. LP, FIL Ltd, Braun Stacey Associates Inc., Wells Fargo & Company MN and SG Americas Securities LLC. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $121.07.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $26.94 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.


MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  928 (Vote Outperform)
Underperform Votes:  489 (Vote Underperform)
Total Votes:  1,417
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $156.8571, suggesting that the stock has a possible upside of 29.56%. The high price target for ALXN is $180.00 and the low price target for ALXN is $120.00. There are currently 1 hold rating and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.952.952.952.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $156.8571$156.5238$153.1905$154.8636
Price Target Upside: 29.56% upside41.28% upside41.06% upside14.54% upside

Alexion Pharmaceuticals (NASDAQ:ALXN) Consensus Price Target History

Price Target History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2018CitigroupBoost Price TargetBuy ➝ Buy$170.00 ➝ $173.00MediumView Rating Details
4/27/2018Credit Suisse GroupSet Price TargetBuy$149.00MediumView Rating Details
4/27/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$151.00 ➝ $155.00LowView Rating Details
4/23/2018Raymond JamesReiterated RatingBuyLowView Rating Details
4/12/2018NomuraBoost Price TargetBuy$165.00LowView Rating Details
3/15/2018Robert W. BairdSet Price TargetBuy$160.00LowView Rating Details
3/15/2018Deutsche BankSet Price TargetBuy$161.00HighView Rating Details
3/9/2018CowenReiterated RatingBuy$163.00LowView Rating Details
2/12/2018SunTrust BanksSet Price TargetBuy$172.00MediumView Rating Details
2/9/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$177.00 ➝ $180.00LowView Rating Details
2/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$148.00 ➝ $151.00LowView Rating Details
2/9/2018Leerink SwannLower Price TargetOutperform ➝ Outperform$166.00 ➝ $153.00LowView Rating Details
2/5/2018Evercore ISIUpgradeIn-Line ➝ OutperformHighView Rating Details
1/4/2018UBSDowngradeStrong-Buy ➝ OutperformMediumView Rating Details
10/24/2017Royal Bank of CanadaBoost Price Target$166.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$170.00N/AView Rating Details
9/5/2017JPMorgan ChaseUpgradeNeutral ➝ Overweight$163.00 ➝ $175.00MediumView Rating Details
7/28/2017OppenheimerUpgradeMarket Perform ➝ Outperform$175.00HighView Rating Details
6/9/2017Goldman SachsReiterated RatingBuy$142.00LowView Rating Details
6/8/2017Jefferies GroupSet Price TargetHold$120.00MediumView Rating Details
5/24/2017BarclaysReiterated RatingOverweight$155.00HighView Rating Details
3/30/2017InstinetReiterated RatingBuy$148.00LowView Rating Details
12/13/2016WedbushReiterated RatingNeutral$135.00N/AView Rating Details
11/30/2016FBR & CoReiterated RatingMarket Perform$130.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00N/AView Rating Details
6/6/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings History and Estimates Chart

Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$1.25$1.37$1.31

Alexion Pharmaceuticals (NASDAQ ALXN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$1.70N/AView Earnings Details
4/26/2018Q1 2018$1.50$1.68$920.50 million$930.90 millionViewN/AView Earnings Details
2/8/2018Q4 2017$1.09$1.48$880.38 million$909.70 millionViewN/AView Earnings Details
10/26/2017Q3 2017$1.32$1.44$864.34 million$859.00 millionViewN/AView Earnings Details
7/27/2017Q2 2017$1.08$1.56$846.15 million$912.00 millionViewN/AView Earnings Details
4/27/2017Q1 2017$1.05$1.38$826.63 million$870.00 millionViewN/AView Earnings Details
2/16/2017Q416$1.25$1.26$840.69 million$831.00 millionViewN/AView Earnings Details
10/27/2016Q316$1.04$1.23$787.07 million$799.00 millionViewListenView Earnings Details
7/28/2016Q216$0.91$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.31$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.18$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.17$1.13$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.05$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$0.99$0.99$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
10/21/2010Q3 2010$0.19$0.15ViewN/AView Earnings Details
7/22/2010Q2 2010$0.15$0.16ViewN/AView Earnings Details
4/22/2010Q1 2010$0.12$0.11ViewN/AView Earnings Details
2/11/2010Q4 2009$0.12$0.12ViewN/AView Earnings Details
10/22/2009Q3 2009$0.11$0.15ViewN/AView Earnings Details
7/23/2009Q2 2009$0.09$0.11ViewN/AView Earnings Details
4/23/2009Q1 2009$0.07$0.08ViewN/AView Earnings Details
2/12/2009Q4 2008$0.05$0.08ViewN/AView Earnings Details
10/23/2008Q3 2008$0.02$0.11ViewN/AView Earnings Details
7/29/2008Q2 2008($0.04)$0.02ViewN/AView Earnings Details
4/30/2008Q1 2008($0.11)($0.03)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.12)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alexion Pharmaceuticals (NASDAQ:ALXN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 95.67%
Insider Trading History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/30/2018Christopher J CoughlinDirectorBuy10,000$120.79$1,207,900.0026,333View SEC Filing  
2/28/2018Heidi L WagnerSVPSell698$119.35$83,306.30View SEC Filing  
2/28/2018Julie O'neillEVPSell1,625$119.83$194,723.75View SEC Filing  
2/8/2018Heidi L WagnerSVPSell1,774$116.31$206,333.9447,212View SEC Filing  
2/8/2018John B MoriartyEVPSell3,363$115.70$389,099.1071,400View SEC Filing  
2/8/2018Ludwig HantsonCEOSell13,245$116.31$1,540,525.95131,425View SEC Filing  
2/8/2018Paul J ClancyCFOSell6,079$116.31$707,048.4995,093View SEC Filing  
2/5/2018Heidi L WagnerSVPSell655$117.26$76,805.3032,635View SEC Filing  
2/5/2018John B MoriartyEVPSell1,261$117.26$147,864.8620,210View SEC Filing  
1/2/2018Ludwig HantsonCEOSell2,553$121.63$310,521.3936,172View SEC Filing  
10/2/2017Heidi L WagnerSVPSell120$140.00$16,800.00View SEC Filing  
9/5/2017Ann M VenemanDirectorSell835$145.81$121,751.355,480View SEC Filing  
9/5/2017Julie O'neillEVPSell4,375$145.44$636,300.0026,092View SEC Filing  
8/28/2017Julie O'neillEVPSell11,160$140.00$1,562,400.0026,704View SEC Filing  
7/31/2017Ann M VenemanDirectorSell700$137.74$96,418.006,315View SEC Filing  
6/15/2017Bros. Advisors Lp BakerDirectorBuy660,779$117.33$77,529,200.07View SEC Filing  
6/14/2017Bros. Advisors Lp BakerDirectorBuy1,348,955$116.32$156,910,445.60View SEC Filing  
6/14/2017Ludwig HantsonCEOBuy10,000$116.72$1,167,200.0038,725View SEC Filing  
3/1/2017Clare CarmichaelEVPSell2,179$131.66$286,887.1433,980View SEC Filing  
3/1/2017Heidi L WagnerSVPSell994$131.65$130,860.1029,646View SEC Filing  
3/1/2017Leonard BellDirectorSell3,978$131.96$524,936.88391,910View SEC Filing  
2/28/2017Carsten ThielEVPSell125$74.52$9,315.0030,197View SEC Filing  
2/28/2017Edward MillerSVPSell590$131.48$77,573.2015,214View SEC Filing  
2/28/2017Leonard BellDirectorSell2,738$131.71$360,621.98391,910View SEC Filing  
2/27/2017Edward MillerSVPSell260$131.20$34,112.0015,214View SEC Filing  
2/27/2017John B MoriartyEVPSell612$131.20$80,294.4045,864View SEC Filing  
2/9/2017John B MoriartyEVPSell167$126.84$21,182.2846,476View SEC Filing  
2/9/2017Leonard BellDirectorSell246$126.84$31,202.64394,648View SEC Filing  
2/7/2017Heidi L WagnerSVPSell1,932$125.97$243,374.0430,241View SEC Filing  
2/7/2017John B MoriartyEVPSell3,538$125.79$445,045.0246,801View SEC Filing  
2/7/2017Leonard BellDirectorSell8,725$125.97$1,099,088.25395,979View SEC Filing  
1/10/2017Leonard BellDirectorSell100$144.99$14,499.00403,719View SEC Filing  
1/9/2017Leonard BellDirectorSell40,065$138.48$5,548,201.20438,497View SEC Filing  
1/5/2017Alvin S ParvenDirectorSell22,659$138.35$3,134,872.6514,305View SEC Filing  
12/12/2016John B MoriartyEVPSell1,044$118.61$123,828.8450,181View SEC Filing  
12/9/2016Carsten ThielEVPSell2,308$130.00$300,040.0030,433View SEC Filing  
11/14/2016Heidi L WagnerSVPSell59$115.10$6,790.9031,936View SEC Filing  
11/4/2016Leonard BellDirectorSell37,317$140.38$5,238,560.46440,936View SEC Filing  
10/31/2016Leonard BellDirectorSell1,300$135.28$175,864.00406,589View SEC Filing  
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.5232,741View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.8937,325View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.2031,995View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.7540,354View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.4416,519View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.0040,579View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.5035,384View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.0038,577View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.006,373View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.006,373View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.1039,577View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48189,266View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.0832,115View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40405,289View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78178,463View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.9651,360View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.4042,706View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.4532,337View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32189,632View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.9241,054View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02193,026View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.3917,215View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40742,222View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02179,862View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50173,026View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.4429,937View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.1430,348View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76746,192View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88171,862View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.0214,215View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00749,259View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00749,259View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.603,252View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.3941,340View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00849,088View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.0036,385View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00919,088View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.5238,310View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00919,088View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.001,032,331View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.9024,426View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.284,840View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.001,032,331View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20101,308View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40113,965View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.8619,670View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00179,217View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20986,696View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00963,276View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.6894,818View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44129,775View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60975,066View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58103,068View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80977,726View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.901,031,957View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.001,031,957View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00179,217View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.001,026,293View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.501,003,519View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.469,463View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.001,036,669View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.531,176,669View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alexion Pharmaceuticals (NASDAQ ALXN) News Headlines

Source:
DateHeadline
Insight into Alexion Pharmaceuticals’ Solid Product PerformanceInsight into Alexion Pharmaceuticals’ Solid Product Performance
finance.yahoo.com - May 18 at 6:02 PM
Analyzing Alexion’s Cash Flows and Valuation MetricsAnalyzing Alexion’s Cash Flows and Valuation Metrics
finance.yahoo.com - May 18 at 6:02 PM
Exploring the Promising Research Pipeline of Alexion TherapeuticsExploring the Promising Research Pipeline of Alexion Therapeutics
finance.yahoo.com - May 18 at 6:02 PM
Alexion Delivered a Solid Financial Performance in Q1 2018Alexion Delivered a Solid Financial Performance in Q1 2018
finance.yahoo.com - May 18 at 6:02 PM
Analyzing Alexion’s Acquisition of Wilson TherapeuticsAnalyzing Alexion’s Acquisition of Wilson Therapeutics
finance.yahoo.com - May 18 at 6:02 PM
$980.63 Million in Sales Expected for Alexion Pharmaceuticals (ALXN) This Quarter$980.63 Million in Sales Expected for Alexion Pharmaceuticals (ALXN) This Quarter
www.americanbankingnews.com - May 15 at 4:39 AM
Alexion Pharmaceuticals (ALXN) Given Consensus Recommendation of "Buy" by BrokeragesAlexion Pharmaceuticals (ALXN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 1:22 AM
$1.68 Earnings Per Share Expected for Alexion Pharmaceuticals (ALXN) This Quarter$1.68 Earnings Per Share Expected for Alexion Pharmaceuticals (ALXN) This Quarter
www.americanbankingnews.com - May 13 at 5:23 AM
Alexion Pharmaceuticals (ALXN) Defended at RBCAlexion Pharmaceuticals (ALXN) Defended at RBC
www.streetinsider.com - May 10 at 5:59 PM
Noteworthy Tuesday Option Activity: ALXN, USAT, FDXNoteworthy Tuesday Option Activity: ALXN, USAT, FDX
www.nasdaq.com - May 8 at 5:41 PM
Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceAlexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 8 at 5:41 PM
Christopher J. Coughlin Buys 10,000 Shares of Alexion Pharmaceuticals (ALXN) StockChristopher J. Coughlin Buys 10,000 Shares of Alexion Pharmaceuticals (ALXN) Stock
www.americanbankingnews.com - May 2 at 7:20 PM
Zacks Investment Research Downgrades Alexion Pharmaceuticals (ALXN) to HoldZacks Investment Research Downgrades Alexion Pharmaceuticals (ALXN) to Hold
www.americanbankingnews.com - May 2 at 12:25 PM
Edited Transcript of ALXN earnings conference call or presentation 26-Apr-18 2:00pm GMTEdited Transcript of ALXN earnings conference call or presentation 26-Apr-18 2:00pm GMT
finance.yahoo.com - April 30 at 5:15 PM
Alexion Pharmaceuticals (ALXN) Price Target Increased to $173.00 by Analysts at CitigroupAlexion Pharmaceuticals (ALXN) Price Target Increased to $173.00 by Analysts at Citigroup
www.americanbankingnews.com - April 30 at 9:31 AM
Alexion Clears A Path For 2nd Generation PNH DrugAlexion Clears A Path For 2nd Generation PNH Drug
seekingalpha.com - April 30 at 8:22 AM
BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch StudyBRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study
www.reuters.com - April 28 at 5:15 PM
Alexion Pharmaceuticals (ALXN) PT Set at $149.00 by Credit Suisse GroupAlexion Pharmaceuticals (ALXN) PT Set at $149.00 by Credit Suisse Group
www.americanbankingnews.com - April 28 at 9:38 AM
Analysts’ Recommendations for Vertex PharmaceuticalsAnalysts’ Recommendations for Vertex Pharmaceuticals
finance.yahoo.com - April 28 at 8:27 AM
Alexion Pharmaceuticals (ALXN) Receives Buy Rating from Stifel NicolausAlexion Pharmaceuticals (ALXN) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - April 27 at 11:22 AM
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%
www.zacks.com - April 27 at 8:28 AM
Zacks: Brokerages Expect Alexion Pharmaceuticals (ALXN) Will Announce Quarterly Sales of $917.52 MillionZacks: Brokerages Expect Alexion Pharmaceuticals (ALXN) Will Announce Quarterly Sales of $917.52 Million
www.americanbankingnews.com - April 27 at 2:38 AM
Alexion Pharmaceuticals (ALXN) Releases Quarterly  Earnings Results, Beats Expectations By $0.18 EPSAlexion Pharmaceuticals (ALXN) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - April 26 at 6:50 PM
Alexion Pharma Q1 revenues up 7%; non-GAAP EPS up 22%; raises revenue guidanceAlexion Pharma Q1 revenues up 7%; non-GAAP EPS up 22%; raises revenue guidance
seekingalpha.com - April 26 at 5:18 PM
Alexion Pharmaceuticals (ALXN) Q1 2018 Results - Earnings Call TranscriptAlexion Pharmaceuticals (ALXN) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 5:18 PM
Alexion shares jump after company raises guidanceAlexion shares jump after company raises guidance
www.marketwatch.com - April 26 at 5:18 PM
Heres Why Alexion Pharmaceuticals Is Surging TodayHere's Why Alexion Pharmaceuticals Is Surging Today
finance.yahoo.com - April 26 at 5:18 PM
Boston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impressBoston-bound Alexion gets $2.5B stock jolt as earnings, drug trial impress
finance.yahoo.com - April 26 at 5:18 PM
Here's Why Alexion Pharmaceuticals Is Surging TodayHere's Why Alexion Pharmaceuticals Is Surging Today
finance.yahoo.com - April 26 at 5:18 PM
Alexion Rockets As New Drug Proves Itself Against Blockbuster SolirisAlexion Rockets As New Drug Proves Itself Against Blockbuster Soliris
finance.yahoo.com - April 26 at 5:18 PM
Why Domino's Pizza, Advanced Micro Devices, and Alexion Pharmaceuticals Jumped TodayWhy Domino's Pizza, Advanced Micro Devices, and Alexion Pharmaceuticals Jumped Today
finance.yahoo.com - April 26 at 5:18 PM
Alexion Pharmaceuticals (ALXN) Updates FY18 Earnings GuidanceAlexion Pharmaceuticals (ALXN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - April 26 at 10:58 AM
Alexion (ALXN) Tops Q1 Earnings and Sales Beat EstimatesAlexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates
www.zacks.com - April 26 at 8:15 AM
Alexion Pharmaceuticals beats by $0.18, beats on revenueAlexion Pharmaceuticals beats by $0.18, beats on revenue
seekingalpha.com - April 26 at 8:15 AM
Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch StudyAlexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
finance.yahoo.com - April 26 at 8:15 AM
Alexion: 1Q Earnings SnapshotAlexion: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 8:15 AM
$1.48 EPS Expected for Alexion Pharmaceuticals (ALXN) This Quarter$1.48 EPS Expected for Alexion Pharmaceuticals (ALXN) This Quarter
www.americanbankingnews.com - April 25 at 5:10 PM
[$$] New Biotech Grabs Series A for Rare Disease Treatments[$$] New Biotech Grabs Series A for Rare Disease Treatments
finance.yahoo.com - April 25 at 8:19 AM
Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings SeasonWhy Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season
finance.yahoo.com - April 24 at 5:36 PM
Alexion Pharmaceuticals (ALXN) Buy Rating Reaffirmed at Raymond JamesAlexion Pharmaceuticals' (ALXN) Buy Rating Reaffirmed at Raymond James
www.americanbankingnews.com - April 24 at 8:20 AM
Alexion Pharmas (ALXN) 4/26 Earnings Will Focus On Brazil - GoldmanAlexion Pharma's (ALXN) 4/26 Earnings Will Focus On Brazil - Goldman
www.streetinsider.com - April 24 at 8:18 AM
Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? April 23, 2018Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? April 23, 2018
www.zacks.com - April 24 at 8:18 AM
Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 23 at 8:14 AM
BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In BrazilBRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil
www.reuters.com - April 22 at 8:16 AM
Alexion Pharma (ALXN) Defended at LeerinkAlexion Pharma (ALXN) Defended at Leerink
www.streetinsider.com - April 22 at 8:16 AM
Alexion Pharmaceuticals (ALXN) Buy Rating Reiterated at UBSAlexion Pharmaceuticals' (ALXN) Buy Rating Reiterated at UBS
www.americanbankingnews.com - April 20 at 9:46 PM
UBS Reiterates Buy Rating for Alexion Pharmaceuticals (ALXN)UBS Reiterates Buy Rating for Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - April 20 at 5:52 PM
Implications from Soliris patent ruling in Brazil likely immaterial says AlexionImplications from Soliris patent ruling in Brazil likely immaterial says Alexion
seekingalpha.com - April 20 at 5:22 PM
Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris (Eculizumab)Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris (Eculizumab)
www.finanznachrichten.de - April 20 at 5:22 PM
Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab)Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab)
finance.yahoo.com - April 20 at 5:22 PM

SEC Filings

Alexion Pharmaceuticals (NASDAQ:ALXN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alexion Pharmaceuticals (NASDAQ:ALXN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alexion Pharmaceuticals (NASDAQ ALXN) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.